HuaXi Pharm investment, marketing by Hongwan Mednet
☆ Rosuvastatin calcium (Rosuvastatin calcium, Brand name: Crestor)
☆ Atorvastatin calcium (Atorvastatin Calcium, Brand name: Liptor)
☆ Compound niacin extended-release tablets (Compoud Niacin Acid and Lovastatin-release Tablets, English trade name: Altocro)
According to the statistics of World Health Organization, the number of Chinese died from of cardiovascular disease or its complications is more than 3 million people every year. Coronary heart disease mortality in the last eight years in the city increased by 53.4% and at an annual rate of 20%. According to statistics, China has two million new stroke patients every year, and 7 million stroke patients undergoing treatment. And 4.5 million patients can not take care of themselves and lose labor ability with varying degrees, in which disability is as high as 75%. Hundreds of thousand stroke patients die each year. Treatment of cardiovascular and cerebrovascular diseases should start from prevention and treatment of hyperlipidemia.
According to recent statistics of Ministry of Health that conducted nationwide it shows that the total prevalence in residents over the age of 18 was 18.6%, the total number of patients reached 160 million. According to the average medication cost per person per day basis, lipid-lowering drug market space is enormous.
2008 China National Nutrition and Health Survey (unit:%)
|
|
Prevalence of dyslipidemia |
Prevalence of high cholesterol |
Increased cholesterol marginal rate |
Prevalence of hypertriglyceridemia |
Low high-density lipoprotein hyperlipidemia prevalence |
|
Residents over the age of 18 |
18.6 |
2.9 |
3.9 |
11.9 |
7.4 |
|
Male |
22.2 |
2.7 |
3.9 |
14.5 |
9.3 |
|
Female |
15.9 |
3.2 |
3.9 |
9.9 |
5.4 |
|
18～44 years old |
17.0 |
1.8 |
2.6 |
10.9 |
7.3 |
|
45~59 years old |
22.9 |
4.7 |
5.9 |
15.7 |
7.2 |
|
Over 60 years old |
23.4 |
6.1 |
6.2 |
4.8 |
7.0 |
|
Urban |
21.0 |
4.1 |
5.1 |
14.2 |
7.1 |
|
Metropolitan |
20.2 |
4.5 |
5.2 |
13.3 |
6.6 |
|
Medium and small citie |
21.3 |
3.9 |
5.1 |
14.6 |
7.4 |
|
Rural |
17.7 |
2.4 |
3.3 |
10.9 |
7.5 |
|
First class of rural |
18.6 |
4.0 |
5.0 |
12.8 |
6.3 |
|
Second class of rural |
16.5 |
2.0 |
3.0 |
9.4 |
7.6 |
|
Third class of rural |
22.2 |
2.0 |
2.6 |
14.3 |
10.1 |
|
Forth class of rural |
17.2 |
1.7 |
2.6 |
11.1 |
7.2 |
According to the global pharmaceutical sales data in 2009, sales of cardiovascular drugs amounted to $ 35.281 billion, representing an increase of 4.9 percent over the same period 2008。 The number one blockbuster Atorvastatin (Liptor, Lipitor) places $13.288 billion，that is 37.64% of cardiovascular drug sales, and ranked first in the world's best-selling drugs, and became influential favorite of the global pharmaceutical market. "Its brother” - Rosuvastatin calcium also performed well. Although statins have been brilliant for many years, it still maintained a strong vitality and absolute power.
According to statistics, China’s lipid-lowering drug market of has grown from $2.5 billion of 2003 to to nearly a billion of 2009 (see Table 1).
Table 1 2003-2009 National cholesterol-lowering drugs market size and trends
|
|
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
|
Sales (billion) |
2.5 |
3.388 |
4.022 |
4.988 |
6.145 |
7.876 |
9.228 |
|
Growth rate |
30.30% |
35.52% |
18.71% |
24.02% |
23.19% |
28.17% |
17.17% |
In Lipid-lowering drug market 2007, the top five varieties in the market take the share of 81.94%. The top five varieties 2009 take 82.05% market share, of which the top four products are statins (respectively: Atorvastatin, Simvastatin, Pravastatin, Fluvastatin) and occupy 77% of the share. There were new adaptive diseases emerging for statins drugs. And in the Chinese market its share of the lipid-lowering drugs increased steadily, currently accounting for more than 90%.
Rosuvastatin is the third generation statins. From currently available clinical data, Rosuvastatin is competitive in statins drugs. The test results show that its efficacy is far better than the competitors in the context of larger doses. Comparing with existing statins, Rosuvastatin calcium can more reduce LDL (low density lipoprotein cholesterol, the so-called "bad cholesterol") levels radically. While being applied in the dose range, it can significantly increase HDL (high-density lipoprotein cholesterol, the so-called "good cholesterol") levels. Rosuvastatin was in the 2009 national health insurance directory. According to statistics, in 2009 Rosuvastatin calcium in our sales is of about ¥0.225 billion.
|
